Characteristics of lung cancers harboring NRAS mutations - Wikidata - awgldk - TriplyDB

Characteristics of lung cancers harboring NRAS mutations

Characteristics of lung cancers harboring NRAS mutations

http://www.wikidata.org/entity/Q28706226

about

Somatic DNA mutation analysis in targeted therapy of solid tumours Targeted therapies in development for non-small cell lung cancer Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Mutant HRAS as novel target for MEK and mTOR inhibitors Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Molecular pathways and therapeutic targets in lung cancer Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.EGFR: The Paradigm of an Oncogene-Driven Lung Cancer Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways c-MET kinase inhibitors: a patent review (2011 - 2013).Prognostic and predictive biomarkers in lung cancer. A review.Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer.Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Diagnosis and Molecular Classification of Lung Cancer.A case report of successful diagnosis of a pulmonary nodule by a survey of oncogenic mutations; primary lung carcinoma or pulmonary metastasis?Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.Standardizing biomarker testing for Canadian patients with advanced lung cancer.Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.

P2860

Q26770324-1F2AA5DA-338C-4F6B-B207-E756A8B14E60 Q27022852-F1C30E37-832A-43BA-AF67-C0753B7695AA Q27853104-E1544989-9463-48A4-B3ED-AE255BF91433 Q27853238-DB96944D-F635-42CE-BC56-E5E208CD7E08 Q27853330-196FFB48-D745-4CB6-9699-8A1D76537399 Q28077504-EDBCD256-8C71-4A72-A423-5AE42AB967CB Q28083446-F0D09BAA-A887-4A4E-AD82-AA20A5F6AB47 Q30487077-E4B381D7-2F79-41FC-953E-67E7E18D7F42 Q33560928-53296CD3-FC3F-456A-B018-2548F65F5E3B Q33688872-EB78240B-2A1A-4856-8763-06CCDE8AFF35 Q33793611-037B98A6-088D-48BC-B415-76271548BE2F Q33906921-F88AA2E6-B248-44DB-A998-DC414B805EBC Q33947862-9023EAC5-7FDF-416B-928E-41B6DAD47DA0 Q34060669-D26998FE-D7F9-4B6A-8420-075B76667C6C Q34175045-98232175-CDCB-46BF-815C-7FD6E8EB0F49 Q34193764-1E7C9DC2-E67F-4876-BD99-B45839C0CB7E Q34365949-2B7C5A81-42BE-4180-878F-6AF344AC0415 Q34781380-5314158C-5731-4B38-90FE-F15D615FFBCE Q35619241-5A59E380-CFE7-4D2B-9458-9031F732D7CB Q35712214-649FCCC6-3612-4045-9D22-ACDCBEE7C5A3 Q36316643-D9F7EA98-0E5E-4591-9ED5-4D42627086FB Q36782414-E0CDA445-CCD2-4BB7-8D64-E5D4239E602B Q36916468-930DE19D-A5C2-446F-979C-6CFCC769BDD0 Q37240015-16950AD0-C7D6-4E3B-837D-887C65F3FB13 Q37692104-1FA409FA-17B8-4818-9D7D-451784DB90AF Q37747447-F0D769D6-F791-42E3-8AF6-249B0BC53547 Q38165247-A13FC545-4877-4287-8660-322F7FCB7592 Q38178187-0B5EDA34-A196-45E9-97EF-6C6997F73CA8 Q38456346-975B12D2-3CB0-4644-A1E2-AB1145E574EE Q38740315-221D263C-336C-4205-8763-70331AEE12FA Q38825099-055B6853-B2E6-4EA8-B21F-47826630EC6A Q38881066-EB1323DF-A565-46DA-A9D2-6F2411E135AA Q38930336-A540264B-88E4-4860-9D59-C6C601469E30 Q40466906-B9D16FBF-5C78-479D-B8CF-0481B29CD1FF Q42003695-4766843C-E7EB-4B42-9027-F8E413A389BC Q44867413-2F31A584-B8E0-4605-BD81-250E7CCEC4CE Q47159292-E28485CC-1EB2-432F-95AB-8DD5285ED40A Q52673091-E2C2AB65-831D-4C56-B7C8-E720C6A75B40 Q53647606-D062F2B7-3A17-45ED-9B02-5859EF22ED50 Q55025386-4A2D60E5-3E56-4EE3-AB0A-90F17D5583C5

P2860

Characteristics of lung cancers harboring NRAS mutations

http://www.wikidata.org/entity/Q28706226

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Characteristics of lung cancers harboring NRAS mutations

@ast

Characteristics of lung cancers harboring NRAS mutations

@en

Characteristics of lung cancers harboring NRAS mutations

@nl

type

label

Characteristics of lung cancers harboring NRAS mutations

@ast

Characteristics of lung cancers harboring NRAS mutations

@en

Characteristics of lung cancers harboring NRAS mutations

@nl

prefLabel

Characteristics of lung cancers harboring NRAS mutations

@ast

Characteristics of lung cancers harboring NRAS mutations

@en

Characteristics of lung cancers harboring NRAS mutations

@nl

P1433

Q28706226-5D22C1F8-EAA1-4BCE-871B-B90DD1EB7826

P1476

Q28706226-7C39ACEE-5078-4861-9813-21CAD41D24BF

P2093

Q28706226-04403CA8-94A3-47FE-93C2-F6D7C3272AFE

Q28706226-0AB2EBB2-32F3-45D0-AE60-9FD92DD81E72

Q28706226-0F4ADB5D-7191-4040-BEF5-FCEC12A8554F

Q28706226-1F230AD2-E609-42B8-B0D2-1400D09F07BA

Q28706226-27095FBE-DA27-48BA-AF25-ECCFE9FD6ED4

Q28706226-29AB1EDB-2356-4679-8EF1-F43B5B79ACBC

Q28706226-4BAF224C-4D19-40AD-AB90-09D34B07506C

Q28706226-5D2CF227-5501-4DF9-AF52-B06CEF926159

Q28706226-69F4F193-0A7E-4CBD-9DFD-0D11621F7262

Q28706226-7AFA66E0-302F-4138-A7A7-AC2C967519C0

P2860

Q28706226-0E92F83E-1794-4E76-A040-C5237B9204A8

Q28706226-199C1C9D-5419-4DBA-AE36-38F5D50FC442

Q28706226-1E914BC6-8909-40B9-875B-E55A6CCE5311

Q28706226-22D9498F-9B01-42D7-8FBF-77649A8EF5BA

Q28706226-2386B89D-0478-4454-8913-95B90B1B0752

Q28706226-23E04411-50C9-4752-9735-AD246467FB0F

Q28706226-23FE91BD-B66A-4724-9E8D-DAB4F88EC0A6

Q28706226-3131535C-ABFB-4696-BD4B-A6C981438493

Q28706226-39BEF8E3-C26C-4D76-903B-2358902D0264

Q28706226-3FEB039E-5913-481D-991B-4FDA0B08DF0D

P304

Q28706226-67D4DEF4-A895-4FBE-983C-F3FBEC0C930C

P31

Q28706226-78E5FBF8-7A12-4FA4-99A8-FF3F39E6A4D5

P3181

Q28706226-F609864A-25E5-4D3F-9802-1D635FA6CECE

P356

Q28706226-4E60299C-FC2F-40CC-B74B-85EB483AE36B

P407

Q28706226-8DF40C91-95B9-4C70-854A-11BB80D88B87

P433

Q28706226-D34E3D71-63C2-455E-88D7-32C344524A17

P478

Q28706226-E571C335-99A8-438C-A2D9-BDE84C831C84

P50

Q28706226-574A49C2-95FC-4E7C-A9CE-BCC902C80E83

Q28706226-77517D5A-1314-4B23-B921-C02F61EB8939

Q28706226-BC02E450-1F64-42BA-95AA-ADF1FD93FE0B

Q28706226-E7018D0D-DFA2-4C88-99F1-16FCD1F7D88D

P577

Q28706226-4AD52B76-3EAB-47F5-8157-B2B3B1685C52

P698

Q28706226-505443C7-DE4D-4C9B-B835-B981AE99DA29

P932

Q28706226-2EA0519A-C8E3-4678-BA74-CD56FD8B435F

P3181

P356

1078-0432.CCR-12-3173

P1433

Clinical Cancer Research

P1476

Characteristics of lung cancers harboring NRAS mutations

@en

P2093

Cindy L Vnencak-Jones

http://www.w3.org/2001/XMLSchema#string

David Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Dora Dias-Santagata

http://www.w3.org/2001/XMLSchema#string

Edward B Garon

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Hidefumi Sasaki

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Lecia V Sequist

http://www.w3.org/2001/XMLSchema#string

Lynne Berry

http://www.w3.org/2001/XMLSchema#string

Marc Ladanyi

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Somatic mutations affect key pathways in lung adenocarcinoma

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

ROS1 rearrangements define a unique molecular class of lung cancers.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Tobacco smoke carcinogens and lung cancer

P304

2584-2591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3627672

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-12-3173

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Christine M. Lovly

P577

2013-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23515407

http://www.w3.org/2001/XMLSchema#string

P932

3643999

http://www.w3.org/2001/XMLSchema#string